The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

[1] Siegel RL(2018)Jemal A (2018) cancer statistics Ca Cancer J Clin 68 7-30

[2] Miller KD(2018)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study JAMA Oncol 4 1553-1568

[3] Fitzmaurice C(2018)Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis World J Surg Oncol 16 8-454

[4] Akinyemiju TF(2018)The biology and management of non-small cell lung cancer Nature 553 446-861

[5] Al Lami FH(2017)Precision diagnosis and treatment for advanced non–small-cell lung cancer N Engl J Med 377 849-712

[6] Chen Y(2014)Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29 Eur J Cancer 50 706-3092

[7] Peng X(2012)Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non–small-cell lung cancer J Clin Oncol 30 3084-673

[8] Zhou Y(2015)Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Transl Lung Cancer Res. 4 515-155

[9] Xia K(2014)Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 665-1639

[10] Zhuang W(2014)Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 15 143-135

[1] Siegel RL(2018)Jemal A (2018) cancer statistics Ca Cancer J Clin 68 7-30

[2] Miller KD(2018)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study JAMA Oncol 4 1553-1568

[3] Fitzmaurice C(2018)Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis World J Surg Oncol 16 8-454

[4] Akinyemiju TF(2018)The biology and management of non-small cell lung cancer Nature 553 446-861

[5] Al Lami FH(2017)Precision diagnosis and treatment for advanced non–small-cell lung cancer N Engl J Med 377 849-712

[6] Chen Y(2014)Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29 Eur J Cancer 50 706-3092

[7] Peng X(2012)Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non–small-cell lung cancer J Clin Oncol 30 3084-673

[8] Zhou Y(2015)Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Transl Lung Cancer Res. 4 515-155

[9] Xia K(2014)Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 665-1639

[10] Zhuang W(2014)Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 15 143-135